Research programme: alpha-synuclein-inhibiting antibodies - Lundbeck

Drug Profile

Research programme: alpha-synuclein-inhibiting antibodies - Lundbeck

Latest Information Update: 17 Oct 2013

Price : $50

At a glance

  • Originator Lundbeck A/S
  • Class Antibodies
  • Mechanism of Action Alpha-synuclein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Parkinson's disease

Most Recent Events

  • 14 Oct 2013 Preclinical trials in Parkinson's disease in Denmark (Parenteral)
  • 14 Oct 2013 Lundbeck secures grant from Michael J. Fox Foundation to finance development of alpha synuclein-inhibiting antibodies for Parkinson's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top